Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approved. Investigators note prevalence of Candida infections in patients on the Novartis drug.
You may also be interested in...
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.